News

Elinzanetant benefits were assessed in younger and older women with moderate hot flashes.
Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline ...
Gilead Sciences (NASDAQ:GILD), a prominent biotechnology player with $28.7 billion in annual revenue and an impressive 78% gross profit margin, received FDA approval for Yeztugo (lenacapavir), its ...
Gilead Sciences is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in California. At one point, the company had been planning to expand ...
Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives ...
Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior day's close.
See disclosure here or remove ads. In other recent news, Gilead Sciences received FDA approval for its new HIV prevention treatment, lenacapavir, marketed as Yeztugo.
Gilead Sciences reported Trodelvy’s Phase 3 test in metastatic urothelial cancer fell short of showing a statistically significant benefit on the overall survival main goal.
Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage trials of obeldesivir.